44 reports

First-generation biologics include insulins, growth hormones, and vaccines made from living cells, such as bacteria, yeast, and mold.

  • Biosimilar
  • World
  • Boehringer Ingelheim GmbH
  • Lonza Group Ltd
  • Samsung Electronics Co., Ltd.

REST OF WORLD PART D: ANNEXURE ##.

  • Biosimilar
  • Europe
  • North America
  • World
  • Market Shares

Human Growth Hormones ##. ##.

  • Biosimilar
  • Medical Biotechnology
  • World
  • Market Size

##. ##. ## Biosimilar Human Insulin in China ##. ##. ## Biosimilar Human Insulin in India ##. ##. ##. ## Wockhardt and Biocon - Given up on their Desire to Target the US and Europe?

  • Biosimilar
  • Medical Biotechnology
  • World
  • Market Shares
  • Market Size

Human Growth Hormones ##. ##. ##. ##. ##.

  • Biosimilar
  • Medical Biotechnology
  • United States
  • Forecast
  • Market Size

Human growth hormone ##. ##. ##.

  • Biosimilar
  • Medical Biotechnology
  • ASEAN
  • China
  • Market Size

Growth Hormone Deficiency ##. ##.

  • Biosimilar
  • Medical Biotechnology
  • United States
  • World
  • Market Size
  • 4.2 HUMAN GROWTH HORMONE (HGH) BIOSIMILARS MARKET AND FORECAST
  • GLOBAL - HUMAN GROWTH HORMONE (HGH) BIOSIMILARS MARKET (MILLION US$), 2008 - 2015

The increasing compliance for human growth hormone drugs and massive unexplored market in the emerging economies, such as India and China are creating opportunities for the growth of the global human growth hormone market.

  • Biosimilar
  • World
  • Market Size
  • Amgen Inc.
  • Biocon Limited

Biosimilars Market By Product, By Technology, By Indication, By Manufacturing Type, By Route of Administration, by Geography - Global Market Size, Share, Development, Growth, and Demand Forecast, 2014-2024 Chapter ##.

  • Biosimilar
  • Europe
  • North America
  • World
  • Market Size

Growth Hormone Deficiency ##. ##.

  • Biopharmaceutical
  • Biosimilar
  • Medical Biotechnology
  • United States
  • Market Size
  • Business Profile

Pfizer' s rare diseases products include BeneFix and Refacto AF/ Xyntha for hemophilia, Genotropin for replacement of human growth hormone; Somavert for acromegaly; and Rapamune for prevention of organ rejection in kidney transplantation among others.

  • Biosimilar
  • Market Size
  • Allergan plc
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Erythropoietin drugs market in EMEA 2016-2021 ($ billions)
  • Share of erythropoietin drugs market in Europe 2016

EMEA is the dominant market, representing ##% of global biosimilar spending. ## biosimilar products are authorized in four molecule classes: human growth hormone, EPO, G-CSF, and tumour necrosis factor (TNF)-inhibitors.

  • Biosimilar
  • World
  • Forecast
  • Amgen Inc.
  • Kyowa Hakko Kirin Co., Ltd.
  • 6.1 Sandoz

Amgen operates in one business segment: human therapeutics.

  • Biosimilar
  • Amgen Inc.
  • Celltrion, Inc.
  • Pfizer Inc.
  • Sandoz Inc.

Market Segmentation by Product Type ##. ## Erythropoietin (EPO) ##. ## Human Growth Hormone (HGH) ##. ## Granulocyte- Colony Stimulating Factor (G-CSF) ##. ## Monoclonal Antibody (mAb) ##. ## Insulin ##. ## Interferon (IFN) ##. ## Others ##.

  • Biosimilar
  • Medical Biotechnology
  • World
  • Market Size

Medium Hospitals IMPACT OF BIOLOGICS IN MUSCULOSKELETAL DISORDERS BIOLOGICS INCLUDE RECOMBINANT INSULIN, HUMAN GROWTH HORMONES, ERYTHROPOIETINSTIMULATING FACTORS, AND MABS.

  • Biosimilar
  • World
  • AbbVie Inc.
  • Amgen Inc.
  • Eli Lilly & Co.
  • HUMAN GROWTH HORMONE (HGH) BIOSIMILARS MARKETS
  • HGH BIOSIMILARS MARKET FORECASTS, ($M), 2013-2020

THE COMPANY MARKETS FOLLOW-ON VERSIONS OF THREE BIOPHARMACEUTICAL DRUGS OMNITROPE (HUMAN GROWTH HORMONE), BINOCRIT (EPOETINALFA) AND ZARZIO (G-CSF).

  • Biosimilar
  • Biocon Limited
  • Hospira, Inc.
  • Roche Group
  • Sandoz Inc.
  • KEY FINDINGS
  • 12.3 TEVA PHARMACEUTICAL

Sandoz entered the biosimilars market in 2006 with the launch of its Omnitrope human growth hormone in the European market.

  • Biosimilar
  • North America
  • United States
  • Market Size
  • Sandoz Inc.

Biosimilars and Follow-On Biologics’ Trends, R& D and Revenue Forecasts 2016-2026: Assess Prospects for MAbs, Fusion Proteins, Insulin, G-CSF, Erythropoietin, Interferons, Growth and Fertility Hormones ##.

  • Biosimilar
  • Medical Biotechnology
  • World
  • Market Shares
  • Market Size

IT IS A RECOMBINANT HUMAN PARATHYROID HORMONE OF ##-##.

  • Biosimilar
  • Musculoskeletal Disorder
  • Oncology
  • Pharmaceutical
  • Amgen Inc.
  • PIPELINE BY AMGEN INC, H1 2020
  • PIPELINE BY ALTEOGEN INC, H1 2020

Its products are used for long-acting human growth hormone, long-acting factor Vlla, breast/ gastric cancer ADC, ovarian cancer ADC, eyelea biosimilar and herceptin biosimilar.

  • Biosimilar
  • Ophthalmology
  • United States
  • Product Initiative
  • Regeneron Pharmaceuticals, Inc.
  • PIPELINE BY BENITEC BIOPHARMA LTD, H1 2020
  • PIPELINE BY ALTEOGEN INC, H1 2020

Its products are used for long-acting human growth hormone, long-acting factor Vlla, breast/ gastric cancer ADC, ovarian cancer ADC, eyelea biosimilar and herceptin biosimilar.

  • Biosimilar
  • Eye Disease
  • Ophthalmology
  • Therapy
  • Regeneron Pharmaceuticals, Inc.
  • PIPELINE BY ALTEOGEN INC, H2 2019
  • PIPELINE BY BENITEC BIOPHARMA LTD, H2 2019

Its products are used for long-acting human growth hormone, long-acting factor Vlla, breast/ gastric cancer ADC, ovarian cancer ADC, eyelea biosimilar and herceptin biosimilar.

  • Biosimilar
  • Eye Disease
  • Ophthalmology
  • Therapy
  • Regeneron Pharmaceuticals, Inc.
  • PIPELINE BY BENITEC BIOPHARMA LTD, H2 2019
  • PIPELINE BY ALTEOGEN INC, H2 2019

Its products are used for long-acting human growth hormone, long-acting factor Vlla, breast/ gastric cancer ADC, ovarian cancer ADC, eyelea biosimilar and herceptin biosimilar.

  • Biosimilar
  • Ophthalmology
  • Pharmaceutical
  • Therapy
  • Regeneron Pharmaceuticals, Inc.

It focuses on advancing drugs for the treatment of diabetes and other serious chronic conditions including hemophilia, human growth hormone (HGH) disorders and obesity.

  • Biosimilar
  • Medical Biotechnology
  • India
  • South Asia
  • Piramal Enterprises Limited

Therapy Area Cardiovascular Central Nervous System Dermatology Ear Nose Throat Disorders Gastrointestinal Genetic Disorders Genito Urinary System And Sex Hormones Hormonal Disorders Infectious Disease Musculoskeletal Oncology Respiratory Women' s Health Immunology No. of Deals

  • Biosimilar
  • United States
  • World
  • Deals & Alliance
  • Sandoz Inc.
  • Factors influencing biologics and biosimilars
  • Comparison between biosimilars and generic small molecules

The product acts by targeting the human epidermal growth factor receptor (EGFR).

  • Biosimilar
  • Biocon Limited
  • Celltrion, Inc.
  • Hospira, Inc.
  • Sandoz Inc.
  • Biosimilars Market: Revenue in USD million, Mexico, 2016-2024
  • North America

Currently, there are more than ## biosimilar products in the Mexican market, divided into four main groups: epoetin, G-CSF, human growth hormone, and insulin.

  • Biosimilar
  • North America
  • United States
  • World
  • Market Size

THE DRUG CANDIDATE ACTS BY BLOCKING GROWTH HORMONE RECEPTOR (GHR) EXPRESSION THEREBY REDUCING LEVELS OF THE HORMONE INSULIN-LIKE GROWTH FACTOR-I (IGF-I) IN THE BLOOD AND IS INVOLVED IN THE TREATMENT FOR DISEASES ASSOCIATED WITH EXCESSIVE GROWTH

  • Biosimilar
  • Monoclonal Antibody
  • United States
  • World
  • Product Initiative
  • PARTNERSHIPS
  • EQUITY OFFERING

Its products are used for long-acting human growth hormone, long-acting factor Vlla, breast/ gastric cancer ADC, ovarian cancer ADC, eyelea biosimilar and herceptin biosimilar.

  • Biosimilar
  • East Asia
  • South Korea
  • Deals & Alliance
  • Alteogen Inc
  • PIPELINE BY BENITEC BIOPHARMA LTD, H2 2018
  • PIPELINE BY ALTEOGEN INC, H2 2018

Its products are used for long-acting human growth hormone, long-acting factor Vlla, breast/ gastric cancer ADC, ovarian cancer ADC, eyelea biosimilar and herceptin biosimilar.

  • Biosimilar
  • Ophthalmology
  • United States
  • World
  • Regeneron Pharmaceuticals, Inc.